Skip to main content

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Caracterización de perfiles proteómicos predictivos de hepatotoxicidad asociada a medicamentos antituberculosos: un estudio exploratorio

IP: Luisa Ibáñez Mora
Collaborators: Xavier Vidal Guitart, Jaume Reventós Puigjaner, Maria Buti Ferret, Xavier Martínez Gómez, Teresa Soriano Sánchez, Israel Molina Romero, Eulàlia Pérez Esquirol, Mònica Sabaté Gallego, Maria Urquizu Padilla, Magda Campins Martí
Funding agency: Instituto de Salud Carlos III
Funding: 150645
Reference: EC08/00250
Duration: 01/01/2009 - 31/12/2012

Unitat de Recerca en Malalties Hepatobiliars

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Lluis Castells Fusté, Francisco Rodríguez Frias, Silvia Sauleda Oliveras, Lluís Palenzuela Díaz, Victor Manuel Vargas Blasco, Maria Buti Ferret, Josep Quer Sivila, Maria Nieves Martell Pérez-Alcalde, Rafael Esteban Mur, Juan Ignacio Esteban Mur, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 54080
Reference: 2009 SGR 383
Duration: 01/01/2010 - 30/04/2014

Variabilidad de la región codificante de la proteina de la capsida viral del virus de la hepatitis B y su relación con el curso de la infección y la respuesta a tratamiento antivirales

IP: Francisco Rodríguez Frias
Collaborators: Maria Buti Ferret
Funding agency: Instituto de Salud Carlos III
Funding: 56265
Reference: PI061512
Duration: 01/01/2007 - 30/12/2009

Testing anti-viral drug resistance and understanding resistance development VIRGIL Network of Excellence Grant No 503359 FP6

IP: Maria Buti Ferret
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 84204
Reference: VIRGIL-503359
Duration: 01/05/2004 - 30/04/2008

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Francisco Javier  Ramos  Gómez

Francisco Javier Ramos Gómez

Shock, Organ Dysfunction and Resuscitation
Read more
Javier Hernandez Losa

Javier Hernandez Losa

Predoctoral researcher
Translational Molecular Pathology
Read more
Marta Valeri Sala

Marta Valeri Sala

Senior Technician - MICINN - C
High Technology Unit (UAT)
Preclinical Core Facilities
Core Facilities Area
Read more
Isabel Mª Garlito Pérez

Isabel Mª Garlito Pérez

Research assistant
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.